Aviva’s Voyager Therapeutics VYGR Stock Holding History

Aviva’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-70,285	Closed	-$654K	–	976
2024 Q1	$654K	Sell	70,285 -12,498	-15%	-$106K	﹤0.01%	768
2023 Q4	$699K	Buy	+82,783	New	+$601K	﹤0.01%	738

Other funds holding VYGR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Aviva's VYGR Position: Q2 2024 in Review

Aviva sold out of Voyager Therapeutics (VYGR) in Q2 2024, closing a stake of 70,285 shares — an estimated $654K sold.

Aviva first reported a position in VYGR in Q4 2023 and held it in 2 quarters. The position peaked at $699K in Q4 2023. 127 funds tracked by Wall St. Rank hold VYGR as of Q2 2024.

Aviva reported no remaining Voyager Therapeutics position as of Q2 2024 after selling out during the quarter.
Aviva sold 70,285 Voyager Therapeutics shares in Q2 2024, an estimated $654K.
Aviva first reported a position in Voyager Therapeutics in Q4 2023 and held it in 2 quarters.
Aviva's Voyager Therapeutics position peaked at $699K in Q4 2023.
127 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2024.

Based on Aviva's 13F filing for Q2 2024, filed 2 Aug 2024.